<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>SourceData</source>
  <date>00000000</date>
  <key>sourcedata.key</key>
  <document>
    <id>5210095 Figure_1-A</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 1-A</infon>
    <infon key="sourcedata_figure_dir">Figure_1-A</infon>
    <passage>
      <offset>0</offset>
      <text>(A) GSCs contain the higher levels of stemness markers (Nestin, SOX2, Musashi-1, NANOG, and OCT4) compared with their DFCs. Total RNAs from GSCs and DFCs were subjected to real-time PCR. The average relative amounts of GSCs were normalized with those of DFCs. Shown are means +S.D. of the normalized mRNA levels of GSCs obtained from the three independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_1-B</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 1-B</infon>
    <infon key="sourcedata_figure_dir">Figure_1-B</infon>
    <passage>
      <offset>0</offset>
      <text>(B) Immunoblotting analysis of markers for stemness (SOX2, Nestin and Musashi-1) and differentiation (GFAP and TUJ1 (Neuron-specific class III beta-tubulin)) in GSCs in comparison with GSC-derived cells at different passage numbers (P1-P7).</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_1-C</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 1-C</infon>
    <infon key="sourcedata_figure_dir">Figure_1-C</infon>
    <passage>
      <offset>0</offset>
      <text>(C) Measurement of the cell doubling time. Approximately 3&#215;104 cells for each of XO8 GSCs and XO8 DFCs were seeded in a 60 mm culture dish and counted every day. The cells were treated with trypsin-EDTA, and the number of viable cells was counted with a hemocytometer. The doubling time was calculated from the cell growth curve over 5 days. Shown are means &#177;S.D. obtained from three independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_1-D</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 1-D</infon>
    <infon key="sourcedata_figure_dir">Figure_1-D</infon>
    <passage>
      <offset>0</offset>
      <text>(D) FACS analysis of CD133 and GFAP using X08 GSCs and DFCs. Data are from representative experiments repeated at least three times.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_1-E</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 1-E</infon>
    <infon key="sourcedata_figure_dir">Figure_1-E</infon>
    <passage>
      <offset>0</offset>
      <text>(E) Immunoblotting analysis of CD133 and GFAP in GSCs in comparison with DFCs.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_1-F-G</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 1-F-G</infon>
    <infon key="sourcedata_figure_dir">Figure_1-F-G</infon>
    <passage>
      <offset>0</offset>
      <text>(F) Quantitation of (G). (G) Equal numbers of XO8 GSCs and DFCs were injected orthotropically into mouse brains. After six weeks, brains were harvested and tumorigenic potential was assessed by evaluating tumor formation. Representative microphotographs of the brain sections of mice injected with XO8 GSCs and XO8 DFC controls.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_2-A-H</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 2-A-H</infon>
    <infon key="sourcedata_figure_dir">Figure_2-A-H</infon>
    <passage>
      <offset>0</offset>
      <text>Cell viability assays were performed as described in Materials and Methods after cells were treated with temozolomide (A), cisplatin (B), adriamycin (C), taxol (D), TRAIL (E), bafilomycin A1 (F), thapsigargin (G), and MG132 (H). Means &#177;S.D. from at least three independent experiments are shown as relative indexes after normalization to those of individual control cells treated with DMSO.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_2-I</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 2-I</infon>
    <infon key="sourcedata_figure_dir">Figure_2-I</infon>
    <passage>
      <offset>0</offset>
      <text>(I) XO8 GSCs and DFCs were treated with 50 nM MG132 for 24 hrs. Cell viability was measured using trypan blue exclusion assay. Error bars represent the mean &#177; SD from three independent experiments. For statistical analysis, student t-test (two-sided, one type) were used. (*P &lt; 0.05).</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_2-J</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 2-J</infon>
    <infon key="sourcedata_figure_dir">Figure_2-J</infon>
    <passage>
      <offset>0</offset>
      <text>(J) XO8 GSCs were treated with MG132 were cultured in 0.3% soft-agar as described in Materials and Methods. The colonies bigger than 100 &#181;m in diameter in four randomly chosen fields were subjected to blind counting. Bars, means +S.D. from three independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_3-A-B</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 3-A-B</infon>
    <infon key="sourcedata_figure_dir">Figure_3-A-B</infon>
    <passage>
      <offset>0</offset>
      <text>(A) XO8 GSCs and DFCs were differentially labeled with PKH67 (green) and PKH26 (red), respectively, and mixed before plated on laminine-coated plates. The cells were treated with 50 nM MG132 and subjected to fluorescent microscopy. Scale bar, 100 &#956;M. (B) Quantitation of (A). Cell numbers from three independent experiments were normalized to those of control cells treated with DMSO and presented as means +S.D. (*p=0.0035, n=3). Student t-test (two-sided, one type) were used for statistical analysis.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_3-C</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 3-C</infon>
    <infon key="sourcedata_figure_dir">Figure_3-C</infon>
    <passage>
      <offset>0</offset>
      <text>(C) The harvested cells from (A) were subjected to FACS analysis.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_3-D</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 3-D</infon>
    <infon key="sourcedata_figure_dir">Figure_3-D</infon>
    <passage>
      <offset>0</offset>
      <text>(D) XO8 GSCs were treated with various PIs (salinosporamide A, epoxomicin, and PS341), followed by cell viability assays. Bars, means &#177;S.D. from three independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_3-E</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 3-E</infon>
    <infon key="sourcedata_figure_dir">Figure_3-E</infon>
    <passage>
      <offset>0</offset>
      <text>(E) XO6, XO8, and XO10 GSCs were treated with MG132 and subjected to cell viability assay. Bars, means &#177;S.D. from three independent experiments. (F) XO6, XO8, and XO10 GSCs were treated with MG132 and subjected to cell viability assay in serum-containing media. Bars, means &#177;S.D. from three independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_4-A</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 4-A</infon>
    <infon key="sourcedata_figure_dir">Figure_4-A</infon>
    <passage>
      <offset>0</offset>
      <text>(A) Immunoblotting of XO8 GSCs and DFCs.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_4-B-C</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 4-B-C</infon>
    <infon key="sourcedata_figure_dir">Figure_4-B-C</infon>
    <passage>
      <offset>0</offset>
      <text>(B) Immunoblotting analysis of Ub in XO8 GSCs and XO8 GSC-derived cells in the course of differentiation (P1-P7). (C) Similar to (B) except that XO6 GSCs were used.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_4-D-E</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 4-D-E</infon>
    <infon key="sourcedata_figure_dir">Figure_4-D-E</infon>
    <passage>
      <offset>0</offset>
      <text>(D) Immunoblotting analysis of ubiquitin ligases and proteasomal subunits in XO8 GSCs and XO8 GSC-derived cells in the course of differentiation (P1-P7). (E) Similar to (E) except that XO6 GSCs were used.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_4-G-H-I</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 4-G-H-I</infon>
    <infon key="sourcedata_figure_dir">Figure_4-G-H-I</infon>
    <passage>
      <offset>0</offset>
      <text>(F-I) In vitro proteasome activity assays were performed as described in Materials and Methods. Bars represent means +S.D. from three independent experiments. For statistical analysis, student t-test (two-sided, one type) were used. * P value: (F), 0.0039; (G), 0.0052; (H), 0.0009, (I) DFC, 0.00032; (I)-HEK293, 0.0039; (I)-HeLa: 0.00051.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_4-J</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 4-J</infon>
    <infon key="sourcedata_figure_dir">Figure_4-J</infon>
    <passage>
      <offset>0</offset>
      <text>(J) XO8 GSCs and XO8 DFCs treated with MG132 as described in Materials and Methods were labeled with annexin V and visualized using fluorescent microscopy. Scale bar, 100 &#956;M.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_4-K</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 4-K</infon>
    <infon key="sourcedata_figure_dir">Figure_4-K</infon>
    <passage>
      <offset>0</offset>
      <text>(K) Cells from (J) were subjected to flow cytometry analysis. Annexin V-positive cell numbers were obtained from three independent experiments and normalized to those of controls cells treated with DMSO. Bars, means +S.D. from three independent experiments. For statistical analysis, student t-test (two-sided, one type) were used. * P value: 6 hrs, 0.0012; 17 hrs, 0.0041.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_4-L</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 4-L</infon>
    <infon key="sourcedata_figure_dir">Figure_4-L</infon>
    <passage>
      <offset>0</offset>
      <text>(L) Cells treated with 50 nM MG132 were subjected to immunoblotting analysis of apoptotic markers.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_5-A-B</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 5-A-B</infon>
    <infon key="sourcedata_figure_dir">Figure_5-A-B</infon>
    <passage>
      <offset>0</offset>
      <text>(A) Real-time PCR analysis of the proteasomal subunits PSMB5, PSMB6, and PSMB7 in XO8 GSCs and XO8 DFCs. Shown are means +S.D. values from the three independent experiments following normalization to those of GSCs. For statistical analysis, student t-test (two-sided, one type) were used. ** P value=PSMB5: 0.053, PSMB6: 0.034, PSMB7: 0.067. (B) Similar to (A) except that the cells were treated with 50 nM MG132 for 17 hrs. Shown are means +S.D. values from the three independent experiments following normalization to those of control cells treated with DMSO. For statistical analysis, student t-test (two-sided, one type) were used. ** P value=PSMB5: 0.022, PSMB6: 0.08, PSMB7: 0.603.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_5-C-D</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 5-C-D</infon>
    <infon key="sourcedata_figure_dir">Figure_5-C-D</infon>
    <passage>
      <offset>0</offset>
      <text>(C) Immunoblotting analysis of proteasomal subunits in XO8 GSCs in comparison with XO8 DFCs at passages 11 and 12. Note that part of Figure 5C is also shown as the left panel of Figure 4A. (D) Same as (C) except that the cells were treated with MG132 for 17 hrs.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_5-E</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 5-E</infon>
    <infon key="sourcedata_figure_dir">Figure_5-E</infon>
    <passage>
      <offset>0</offset>
      <text>(E) Immunoblotting analysis of the NF-&#954;B pathway in XO8 GSCs and XO8 DFCs.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_5-F</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 5-F</infon>
    <infon key="sourcedata_figure_dir">Figure_5-F</infon>
    <passage>
      <offset>0</offset>
      <text>(F) Fractionation analysis of NF-&#954;B in XO8 GSCs and XO8 DFCs treated with 50 nM MG132 for 17 hrs. PARP1 and tubulin were used as markers for the nucleus and cytoplasm, respectively.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_5-G</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 5-G</infon>
    <infon key="sourcedata_figure_dir">Figure_5-G</infon>
    <passage>
      <offset>0</offset>
      <text>(G) Immunoblotting analysis of JNK and p38.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_5-H</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 5-H</infon>
    <infon key="sourcedata_figure_dir">Figure_5-H</infon>
    <passage>
      <offset>0</offset>
      <text>(H) Cell viability assay was performed as in Fig. 2 with cells treated with MG132 alone or in combination with SB203580. Shown are means +S.D. values from three independent experiments following normalization to those of control cells treated with DMSO. For statistical analysis, student t-test (two-sided, one type) were used. ** P value = 0.724, 0.502, 0.439 for 0.5, 1.0 and 5.0 &#956;M SB203580, respectively at 0.1 &#956;M MG132, and 0.760, 0.683, 0.498 for 0.5, 1.0 and 5.0 &#956;M SB203580, respectively at 0.5 &#956;M MG132.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_5-I</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 5-I</infon>
    <infon key="sourcedata_figure_dir">Figure_5-I</infon>
    <passage>
      <offset>0</offset>
      <text>(I) Experimental conditions were similar to (H) except that SP600129 was used. Shown are means +S.D. values from three independent experiments following normalization to those of control cells treated with DMSO. For statistical analysis, student t-test (two-sided, one type) were used. * P value = 0.009, 0.002, 0.07 for 0.5, 1.0 and 5.0 &#956;M SP600129, respectively at 0.1 &#956;M MG132, and 0.018, 0.025, 0.09 for 0.5, 1.0 and 5.0 &#956;M SP600129, respectively at 0.5 &#956;M MG132.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_5-J</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 5-J</infon>
    <infon key="sourcedata_figure_dir">Figure_5-J</infon>
    <passage>
      <offset>0</offset>
      <text>(J) Immunoblotting analysis of XO8 GSCs treated with 50 nM MG132 alone or in combination with the JNK inhibitor SP600129.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_6-A</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 6-A</infon>
    <infon key="sourcedata_figure_dir">Figure_6-A</infon>
    <passage>
      <offset>0</offset>
      <text>(A and B) XO8 GSCs and XO8 DFCs were treated with 50 nM MG132 for indicated hours. The expression of genes was assessed by real-time PCR using total RNA extracted from MG132-treated cells. Mean +S.D. values from the three independent experiments are shown after normalization to that of control cells treated with DMSO.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_6-B</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 6-B</infon>
    <infon key="sourcedata_figure_dir">Figure_6-B</infon>
    <passage>
      <offset>0</offset>
      <text>(A and B) XO8 GSCs and XO8 DFCs were treated with 50 nM MG132 for indicated hours. The expression of genes was assessed by real-time PCR using total RNA extracted from MG132-treated cells. Mean +S.D. values from the three independent experiments are shown after normalization to that of control cells treated with DMSO.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_6-C</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 6-C</infon>
    <infon key="sourcedata_figure_dir">Figure_6-C</infon>
    <passage>
      <offset>0</offset>
      <text>(C) XO8 GSCs and XO8 DFCs treated with 50 nM MG132 as described in (A) were subjected to immunoblotting.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_6-D</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 6-D</infon>
    <infon key="sourcedata_figure_dir">Figure_6-D</infon>
    <passage>
      <offset>0</offset>
      <text>(D) XO8 GSCs were treated with MG132, salinosporamide A, epoxomicin, or bortezomib for 24 hrs. Cell lysates were subjected to immunoblot analysis with anti-PARP-1, anti-CHOP, anti-ATF3, anti-ATF3, and anti-BiP antibodies.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_6-E</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 6-E</infon>
    <infon key="sourcedata_figure_dir">Figure_6-E</infon>
    <passage>
      <offset>0</offset>
      <text>(E) XO8 cells were treated with 50 nM MG132 in the absence or presence of 5&#956;M actinomycin D (ActD) for 6 h. The level of ATF3 mRNA was measured using semi-quantitative real-time PCR in comparison with &#946;-actin.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_7-A</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 7-A</infon>
    <infon key="sourcedata_figure_dir">Figure_7-A</infon>
    <passage>
      <offset>0</offset>
      <text>(A) HEK293 cells were transfected with ATF3 shRNA or vector (pLKO1), treated with 50 nM MG132, and then subjected to immunoblotting.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_7-B</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 7-B</infon>
    <infon key="sourcedata_figure_dir">Figure_7-B</infon>
    <passage>
      <offset>0</offset>
      <text>(B) Individualized XO8 GSCs were transduced with lentiviral shRNAs against ATF3 or control as described in Materials and Methods. After four days, individualized GSCs were treated with 50 nM MG132, and subjected to immunoblotting.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_7-C</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 7-C</infon>
    <infon key="sourcedata_figure_dir">Figure_7-C</infon>
    <passage>
      <offset>0</offset>
      <text>(C) XO8 GSCs were transfected with control or CHOP siRNA for 48 hrs and then treated with 50 nM MG132 for 24 hrs. Cell viability was determined using the Trypan blue exclusion assay. Error bars represent the mean &#177; SD from three independent experiments (*P &lt; 0.05, n=3). For statistical analysis, student t-test (two-sided, one type) were used.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_7-D</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 7-D</infon>
    <infon key="sourcedata_figure_dir">Figure_7-D</infon>
    <passage>
      <offset>0</offset>
      <text>(D) Immunoblotting analysis of (C). The cells were collected, lysed, and subjected to immunoblot analysis with indicated antibodies.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_7-E</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 7-E</infon>
    <infon key="sourcedata_figure_dir">Figure_7-E</infon>
    <passage>
      <offset>0</offset>
      <text>(E) Wild-type and CHOP-/- MEF cells were treated with MG132 for 24 hrs. Cell viability was determined using trypan blue exclusion assay. Error bars represent the mean &#177; SD from three separate experiments (*P &lt; 0.05, n=3). For statistical analysis, student t-test (two-sided, one type) were used.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_7-F</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 7-F</infon>
    <infon key="sourcedata_figure_dir">Figure_7-F</infon>
    <passage>
      <offset>0</offset>
      <text>(F) Cell lysates obtained in (E) were subjected to immunoblot analysis with anti-PARP-1, anti-CHOP or anti-ATF3 antibody.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_7-G</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 7-G</infon>
    <infon key="sourcedata_figure_dir">Figure_7-G</infon>
    <passage>
      <offset>0</offset>
      <text>(G) The expression of NOXA was assessed with real-time PCR using total RNA extracted from XO8 GSCs treated with 50 nM MG132 alone or in combination with each inhibitor of ER stress-driven apoptosis (salubrinal; 15 &#181;M, STK064652; 20 &#181;M, STK047915; 20 &#181;M). The mean +S.D. values from the three independent experiments are shown after normalization to that of control cells treated with DMSO. For statistical analysis, student t-test (two-sided, one type) was used. * P value: salubrinal, 0.0003; STK064650, 0.0036; STK047915, 0.0019.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_7-H</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 7-H</infon>
    <infon key="sourcedata_figure_dir">Figure_7-H</infon>
    <passage>
      <offset>0</offset>
      <text>(H) Similar to (G) except that XO8 GSC transduced with lentiviral shRNAs were treated with MG132. The mean +S.D. values from the three independent experiments are shown after normalization to that of control cells treated with DMSO. For statistical analysis, student t-test (two-sided, one type) was used. * P value: #1, 0.026; #5, 0.0033; #6, 0.0482.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_7-I</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 7-I</infon>
    <infon key="sourcedata_figure_dir">Figure_7-I</infon>
    <passage>
      <offset>0</offset>
      <text>(I) XO8 GSCs were treated with 20 nM MG132 alone or in combination with each inhibitor as described in (C), and subjected to immunoblotting. Sal.: salubrinal.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_8-A-E</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 8-A-E</infon>
    <infon key="sourcedata_figure_dir">Figure_8-A-E</infon>
    <passage>
      <offset>0</offset>
      <text>(A and B) XO8 GSCs were subcutaneously (s.c.) injected in the flank of mice. When the tumor volume reached approximately 180 mm3, GSC-bearing mice were administered intraperitoneally (i.p.) with 1 mg/kg MG132 and 10 mg/kg STK alone or in combination on every day for 2 weeks. Tumors were dissected from the subcutaneous regions of nude mice. Inset picture shows the tumor in respective group. Therapeutic effects were monitored using bioluminescence imaging. (C) The bar diagram represents the tumor volumes. (D) Tumor weights were determined at the end of the study. (E) The tumor sizes in each group were determined by histological analysis at day 21 after tumor inoculation.</text>
    </passage>
  </document>
  <document>
    <id>5210095 Figure_8-F</id>
    <infon key="sourcedata_document">2587</infon>
    <infon key="doi">10.15252/embr.201642360</infon>
    <infon key="pmc_id">5210095</infon>
    <infon key="figure">Figure 8-F</infon>
    <infon key="sourcedata_figure_dir">Figure_8-F</infon>
    <passage>
      <offset>0</offset>
      <text>(F) XO10 GSC were orthotopically injected into the brains of BALB/c nude mice. STK047915, MG132, or both were injected intraperitoneally to GSCs-bearing mice at day 14 after XO10 (5&#215;105 cells) inoculation. The PBS was used as a control. Representative photographs of H&amp;E staining from each group show tumor growth. Magnification, &#215;1.</text>
    </passage>
  </document>
</collection>
